摘要
目的观察EMT(上皮-间叶细胞转变)在小鼠肝纤维化进展过程中的动态变化,及骨形成蛋白-7(BMP-7)治疗后对其的影响。方法健康雄性ICR小鼠30只分为对照组(6只)、模型组(18只)和治疗组(6只),模型组再按造模不同时间点分4、8、12周3个亚组,每组6只。模型组的小鼠皮下注射四氯化碳(CCl4)制备肝纤维化小鼠模型,治疗组在造模后第8周开始腹腔注射人重组BMP-7持续4周。造模后各组小鼠下腔静脉采血测定血清检测ALT、AST和白蛋白(Alb);肝组织经HE和Masson染色后光学显微镜下观察各组病理变化;采用RT-PCR检测mRNA表达情况。结果模型组12周可见完整假小叶形成;模型组血清ALT、AST升高、Alb降低,12周时达高峰,治疗组有所缓解,各组间比较差异有统计学意义(P<0.05)。随着纤维化的发生E钙黏蛋白的表达逐渐降低,BMP-7治疗组表达量相对于模型组明显增高(P<0.05)。α-SMA在纤维化发生过程中表达量逐渐增高,BMP-7治疗组表达量相对于模型组明显降低(P<0.05)。结论随着肝纤维化的发生发展EMT过程逐渐加强,而BMP-7能抑制EMT的发生。
Objective To demonstrate the antifibrotic effect of BMP -7, and characterizethe profile of epithelial mesenchymahran- strationduring hepatic fibrogenesis and after treatmentof BMP7. Methods Thirty male ICR mouse were randomly divided into three groups： control group （6mouse） , model group （18mouse） and BMP -7 treated group （6mouse）, and the model group was further divid- ed into three subgroups according to the different time point： 6 weeks （6mouse）, 8 weeks （6mouse） ,12 weeks, （6mouse）. Liver fibro- sis was induced in the model and BMP - 7 treated groups by hypodermic injection of carbon tetrachloride for 12 weeks. BMP - 7 treated group were administrated intraperitoneally with human recombinant BMP - 7 beginning 8 weeks after the first administration of CCl4 lasted for 4 week. All the liver and blood examples were preserved for further study. RT - PCR was used for detecting mRNA expression. Results The improvement of liver function was observed after administration of BMP - 7. Conclusion Increased level of EMTwas accompanied with the progression of hepatic fibrosis, and exogenousBMP - 7 appeared to suppress EMT.
出处
《医学研究杂志》
2012年第11期133-137,共5页
Journal of Medical Research
